The tumor ablation market was valued at $1,413.85 million in 2022 and is estimated to reach $5,032.44 million by 2032, exhibiting a CAGR of 13.5% from 2022 to 2032. Tumor ablation techniques, also referred to as minimally invasive technology, are used to treat tumors of kidney, bones, liver, and lungs. They use heat to target a specific tumor cell. It is a needle-like device with a heat-generating component that leads to cellular necrosis of targeted tumor cell. It is performed in-vivo, without taking tumors out of the body.
The method eliminates benign tumors by inserting a probe and heating it to 100 degrees Celsius under precise computer tomography. There are different methods available for tumor ablation such as microwave ablation, radiofrequency ablation, cryoablation, and others that can be used for disease diagnosis and treatment. Repeated use of ablation methods helps reduce patient's pain and risk while increasing accuracy and treating a broader type of cancer.
The growth of the global tumor ablation market is majorly driven by increase in prevalence of cancer, and high adoption of the tumor ablation-based treatments. Moreover, adoption and emergence of technologically advanced tumor ablation techniques including the advent of thermal and laser ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU) are the factors that influence the market growth. Increase in safety regarding use of ablation techniques, increase in geriatric population, and increase in public-private initiatives & funding to support ongoing research activities related to tumor ablation drive the market growth.
Cancer, a devastating and potentially life-threatening disease, has been steadily increasing in incidence across the globe. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S. This surge can be attributed to several factors, including an aging population, lifestyle changes, and improved diagnostics that enable earlier detection of tumors. Tumor ablation techniques have gained significant prominence in the field of oncology due to their ability to destroy cancerous tissue without the need for extensive surgeries.
Additionally, tumor ablation techniques are often utilized for patients who are not candidates for surgery or as a palliative option to relieve symptoms in advanced cancer cases. The increasing prevalence of cancer not only drives the demand for tumor ablation procedures but also stimulates ongoing research and development efforts to enhance the efficacy and accessibility of these treatments. This, in turn, fosters innovation in the tumor ablation market, leading to the introduction of advanced technologies and improved devices, which further boosts market growth. Thus, the rise in prevalence of cancer is expected to drive the growth of the market.
Furthermore, the high adoption of tumor ablation-based treatments has emerged as a major driving factor for the growth of the tumor ablation market. Tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have gained significant popularity in recent years due to their effectiveness in treating various types of tumors, including liver, lung, kidney, and bone tumors. Tumor ablation procedures offer several distinct advantages over traditional surgical methods. They are minimally invasive, which means they involve smaller incisions or, in some cases, no incisions at all. This results in shorter recovery times, reduced hospital stays, and lower post-operative complications, making them more attractive options for both patients and healthcare providers.
For instance, according to a 2021 report by the National Library of Medicine, it was reported that percutaneous ablation is safe and nearly as efficacious as surgery, usually requiring a lower cost and shorter hospital stay for single hepatocellular carcinoma. In addition, advancements in technology and imaging have greatly improved the precision and accuracy of tumor ablation procedures. Real-time imaging guidance, such as ultrasound, CT scans, or MRI, allows medical professionals to precisely target and monitor the tumor during the ablation process, ensuring thorough destruction of the cancerous tissue while sparing healthy surrounding organs and tissues. Thus, the surge in adoption of tumor ablation-based treatments is expected to significantly contribute to the growth of the market.
However, side-effects associated with tumor ablation treatment might restrain the growth of the market. Moreover, a rise in research and development activities for tumor ablation is expected to present significant growth opportunities to the market. The tumor ablation market is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major key players that operate in the global tumor ablation market are Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra LifeSciences Holding Corporation, AngioDynamics Inc, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation.
The method eliminates benign tumors by inserting a probe and heating it to 100 degrees Celsius under precise computer tomography. There are different methods available for tumor ablation such as microwave ablation, radiofrequency ablation, cryoablation, and others that can be used for disease diagnosis and treatment. Repeated use of ablation methods helps reduce patient's pain and risk while increasing accuracy and treating a broader type of cancer.
The growth of the global tumor ablation market is majorly driven by increase in prevalence of cancer, and high adoption of the tumor ablation-based treatments. Moreover, adoption and emergence of technologically advanced tumor ablation techniques including the advent of thermal and laser ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU) are the factors that influence the market growth. Increase in safety regarding use of ablation techniques, increase in geriatric population, and increase in public-private initiatives & funding to support ongoing research activities related to tumor ablation drive the market growth.
Cancer, a devastating and potentially life-threatening disease, has been steadily increasing in incidence across the globe. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S. This surge can be attributed to several factors, including an aging population, lifestyle changes, and improved diagnostics that enable earlier detection of tumors. Tumor ablation techniques have gained significant prominence in the field of oncology due to their ability to destroy cancerous tissue without the need for extensive surgeries.
Additionally, tumor ablation techniques are often utilized for patients who are not candidates for surgery or as a palliative option to relieve symptoms in advanced cancer cases. The increasing prevalence of cancer not only drives the demand for tumor ablation procedures but also stimulates ongoing research and development efforts to enhance the efficacy and accessibility of these treatments. This, in turn, fosters innovation in the tumor ablation market, leading to the introduction of advanced technologies and improved devices, which further boosts market growth. Thus, the rise in prevalence of cancer is expected to drive the growth of the market.
Furthermore, the high adoption of tumor ablation-based treatments has emerged as a major driving factor for the growth of the tumor ablation market. Tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have gained significant popularity in recent years due to their effectiveness in treating various types of tumors, including liver, lung, kidney, and bone tumors. Tumor ablation procedures offer several distinct advantages over traditional surgical methods. They are minimally invasive, which means they involve smaller incisions or, in some cases, no incisions at all. This results in shorter recovery times, reduced hospital stays, and lower post-operative complications, making them more attractive options for both patients and healthcare providers.
For instance, according to a 2021 report by the National Library of Medicine, it was reported that percutaneous ablation is safe and nearly as efficacious as surgery, usually requiring a lower cost and shorter hospital stay for single hepatocellular carcinoma. In addition, advancements in technology and imaging have greatly improved the precision and accuracy of tumor ablation procedures. Real-time imaging guidance, such as ultrasound, CT scans, or MRI, allows medical professionals to precisely target and monitor the tumor during the ablation process, ensuring thorough destruction of the cancerous tissue while sparing healthy surrounding organs and tissues. Thus, the surge in adoption of tumor ablation-based treatments is expected to significantly contribute to the growth of the market.
However, side-effects associated with tumor ablation treatment might restrain the growth of the market. Moreover, a rise in research and development activities for tumor ablation is expected to present significant growth opportunities to the market. The tumor ablation market is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major key players that operate in the global tumor ablation market are Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra LifeSciences Holding Corporation, AngioDynamics Inc, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2022 to 2032 to identify the prevailing tumor ablation market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Market share analysis of players by products/segments
- New Product Development/ Product Matrix of Key Players
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis / Price Point Analysis
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- Other Ablation Technologies
By Treatment
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
By Application
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Bone Cancer
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Olympus Corporation
- AngioDynamics, Inc.
- Bioventus LLC
- Johnson & Johnson
- Medtronic plc
- ConMed Corporation
- Smith & Nephew plc
- Integra LifeSciences Holdings Corporation
- HealthTronics, Inc.
- Boston Scientific Corporation
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY
CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT
CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION
CHAPTER 7: TUMOR ABLATION MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, the tumor ablation market was valued at $1.3 billion in 2021, and is estimated to reach $4.7 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031.Tumor ablation is a minimally invasive technique commonly used in the treatment of tumors of the kidney, lung, liver, and bone. Ablation is a technique that uses needles to destroy cancerous cells. This procedure eliminates benign growths without trying to remove them from the body. It can be performed through microwave ablation, radiofrequency ablation, irreversible electroporation ablation, and cryo-ablation.
Key factors driving the growth of the tumor ablation market include growing demand for minimally invasive surgeries including tumor ablation techniques. This is attributed to rise in research and development of technologically advanced minimally invasive techniques. For instance, Abbott Laboratories announced the launch of its IonicRF Generator, in November 2022, a radiofrequency ablation device used to target particular nerves with heat in attempt to prevent pain signals from reaching the brain. Furthermore, minimally invasive tumor ablation techniques gaining traction due to various advantages such as accuracy, specificity, painless, and safety. Moreover availability of product that offers a non-surgical, minimally invasive method of treating nervous system discomfort further contribute toward the market growth. Therefore, growing awareness regarding minimally invasive tumor ablation techniques propel growth of tumor ablation market.
The market also offers growth opportunities to the key players in the market. Growing number of research activities for tumor ablation by the various cancer research organization and market key players is expected to create opportunities for market growth during the forecast period. For instance, Medtronic plc, a global leader in medical technologies, announced the U.S. food and drug administration (FDA) approval for its DiamondTemp Ablation (DTA) system. This is the first FDA approved temperature controlled system designed to deliver heat during ablation procedure to allow destruction of target cells. Moreover, growing demand for tumor ablation techniques in developing countries such as Japan and China is expected to create new opportunities for market growth.
The tumor ablation market is segmented into technology, treatment, application, and region. On the basis of material, the market is categorized into stainless steel, glass, ceramic, and PET plastic. On the basis of technology, it is categorized into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. On the basis of treatment, it is fragmented into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is further divided into kidney cancer, liver cancer, breast cancer, lung cancer, and prostate cancer. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Abbott Laboratories, AngioDynamics Inc., Bioventus, Boston Scientific Corporation, ConMed Corporation, Elekta Inc., Galil Medical Inc., HealthTronics Inc., Johnson & Johnson, and Medtronic plc. The players in the market have been actively engaged in the adoption various strategies such as product approval, product launch and expansion to remain competitive and gain advantage over the competitors in the market. For instance, in July 30, 2020, Ethicon a part of Johnson & Johnson Company received product approval for trans-bronchial NeuWave microwave ablation technology.
Key Market Insights
By technology, the others segment was the highest revenue contributor to the market in 2021, and is estimated to reach $1.54 billion by 2031, with a CAGR of 13.6%. However, the microwave ablation segment is estimated to be the fastest-growing segment with a CAGR of 14.7% during the forecast period.By treatment, the surgical ablation segment dominated the global market in 2021. However, the percutaneous ablation segment is expected to be the fastest-growing segment during the forecast period.
Based on application, the liver cancer segment was the highest revenue contributor to the market in 2021.
Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 15.1% during the forecast period.
Companies Mentioned
- Olympus Corporation
- AngioDynamics, Inc.
- Bioventus LLC
- Johnson & Johnson
- Medtronic plc
- ConMed Corporation
- Smith & Nephew plc
- Integra LifeSciences Holdings Corporation
- HealthTronics, Inc.
- Boston Scientific Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
